Settlement Reached in Ozempic Patent Battle

NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the generic version of Ozempic—a medication used for controlling blood sugar and weight loss. The settlement terms remain confidential.

NATCO Pharma Ltd revealed on Monday a significant legal development involving its partner Mylan Pharmaceuticals Inc, which has reached a patent settlement with Novo Nordisk regarding generic Ozempic in the United States.

This accord centers on Ozempic (Semaglutide), a prescription treatment by Novo Nordisk, which Mylan and NATCO are working to develop a generic version of.

The terms of this settlement are confidential, stemming from a US court litigation against Mylan by Novo Nordisk for patent infringement related to Ozempic.

(With inputs from agencies.)